Merck (MRK) and Eisai (ESAIY) give update on Phase 3 LITESPARK-012 trial evaluating first-line combination treatments for certain patients with advanced Renal Cell Carcinoma
Context
Merck and Eisai's update on their Phase 3 trial for a new treatment in advanced Renal Cell Carcinoma could signal significant advancements in the oncology space. If the results are positive, it may boost investor confidence in both companies and influence broader market sentiment in pharmaceuticals, particularly within European markets.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#GERMANY#EUROPE#MERCK & CO INC#MRK.US#MERCK KGAA#EQUITIES#EU SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#DAX 40 INDEX#MRK#US EQUITIES